Navigation Links
Need For Low Cost, Heat Stable HIV Drug in Developing Countries

Medicins Sans Frontieres (MSF), an International humanitarian group has criticized the practice of marketing new or improved drugs in the developed countries and less adapted drugs in the Asian, African and Latin American countries //, where the need is more felt. More than 60, 000 patients in these regions benefit from the anti-retroviral treatment provided by the concern.

The drug known as ritonavir belongs to a class of compounds referred to as protease inhibitors. The latest version of the drug that is heat stable was launched for sale in the US in November 2005. The drug does not require refrigeration for storage, making it ideal for use in hot climates, prevalent in most developing countries.

The provision of new or improved versions of anti-retroviral drugs to HIV infected people in developing or poorly developed countries can make a huge difference. Despite this fact, a lot of people are denied access to such drugs on account of low affordability.

Although sub-Saharan Africa represents only about 10% of the world’s population, more than 60% of people in this region are afflicted with HIV/AIDS. The development of drug resistance to the first line of anti-retroviral poses a significant challenge to management of the AIDS epidemic in these regions. Such patients have to be provided with the drug lopinavir/ritonavir as a second line of treatment.

In line with the above situation, MSF would soon place an order for a heat stable form of the drug, lopinavir. Abbott Laboratories in Chicago currently markets the drug exclusively in the United States at an average wholesale price of 9,687 U.S. dollars.

'With the high temperatures and with the numerous daily electrical blackouts, our patients can't use the old version of this drug. It's a cruel irony that although this drug with no need for refrigeration seems to have been designed for places like Kenya, it is not available here,' said Dr. Christine Genevier, head of mission for MSF's AIDS treatment programs in Kenya.

'But when MSF inquired about the price and availability of this new product for its patients, Abbott responded that it would wait until the product was available in Europe before requesting marketing approval in developing countries. This means a potential delay of years before this drug reaches the people who can benefit from it most,'the MSF said.

Based on the evidence that the new heat stable formulation is associated with a reduced cost of production, the MSF has urged the US based pharmaceutical company to manufacture the drug and market the drug at an optimal price, not exceeding the amount charged for the older version in developing countries.

A letter drafted reflecting the concern of researchers, doctors and AIDS organizations from around the world has been forwarded to the CEO of Abbott Laboratories, urging the immediate supply of cost-effective ritonavir in developing countries.


'"/>




Related medicine news :

1. Due to Cost, Heart Attack Patients Often Avoid Follow-up Care and Medication
2. A.U. Health Ministers Receive Plan To Produce Low-Cost, Generic Drugs in Africa
3. Rahul Mahajans Condition Is Serious But Stable : Hospital
4. Togadiyas Condition Stable After Undergoing Angioplasty
5. Successfully Separated Conjoined Twins In A Critical Yet Stable Condition
6. Cancer Rates Falls In Younger Men But Stable In Young Women
7. Indonesian Siamese Twins With Three Legs In Stable Condition
8. Drugs Delivery Revolutionized by Extremely Stable Glass
9. Saif Ali Khan Recovering and Stable
10. Risk Of Developing Arthritis
11. Developing HIV fighter
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/30/2016)... ... April 30, 2016 , ... Create an abstract ... can distort and manipulate three-dimensional shapes with ease all within Apple Motion ... lines, polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, twist, ...
(Date:4/30/2016)... ... April 30, 2016 , ... The Hacking Medicine ... program to critically evaluate and rank health-focused applications and connected devices for better ... independent, unbiased and accurate information to help accelerate patient and provider adoption of ...
(Date:4/30/2016)... , ... April 30, 2016 , ... ... Boise, President and CEO of EMED, today signed a multifaceted agreement which will ... and the Northern Caribbean University Department of Natural and Applied Sciences, Allied Health ...
(Date:4/30/2016)... ... 30, 2016 , ... “Aging well is a challenge for all of us, but there are things we can ... Kohli . “Research is showing more and more that there are simple, yet important steps ... as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, , ...
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent ... Pick Up Springboard, an automotive invention that improves the storage features of a ... $162 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... TOKYO , April 28, 2016 /PRNewswire/ ... Ahuja , George Phillips und ... wachsenden Unternehmens    ArisGlobal®, ein ... Life Sciences, gab heute bekannt, dass neue ... wachsenden Unternehmens gestoßen sind, die vielfältige Erfahrungen ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
Breaking Medicine Technology: